ERBB2 and neoplasm: Deruxtecan (DX-d) is another payload with anti-TOP1 activity that recently reached the therapeutic armamentarium with the anti-HER2 trastuzumab deruxtecan (T-DXd) and already approved for breast cancer and under development for several tumor types.